



A Review of Portable Electronic Spirometers: Implications for Asthma Self-Management

Delesha M. Carpenter¹ · Reina Jurdi² · Courtney A. Roberts¹ · Michelle Hernandez³ · Robert Horne⁴ · Amy Chan⁴

Published online: 25 August 2018
© Springer Science+Business Media, LLC, part of Springer Nature 2018

Abstract

Purpose of Review Although portable electronic spirometers allow for at-home lung function monitoring, a comprehensive review of these devices has not yet been conducted. We conducted a systematic search and review of commercially available portable electronic spirometers designed for asthma patient use.

Recent Findings All devices ($N = 16$) allowed for monitoring of basic lung function parameters, but only 31% provided in-app videos on how to perform breathing maneuvers. Most devices (63%) provided graphical representations of lung function results, but only 44% gave immediate feedback on the quality of the breathing maneuver. Several devices (25%) were FDA-approved and cost ranged from US\$99 to \$1390. Information on data security (63%), measurement accuracy (50%), and association with patient outcomes (0%) was commonly limited.

Summary This review found that providers' ability to make informed decisions about whether asthma patients may benefit from portable electronic spirometers is limited due to lack of patient outcome data.

Keywords Spirometry · Asthma · mHealth · eHealth · Self-management

Introduction

Asthma is a reversible chronic respiratory disease with an underlying inflammatory basis. It is marked by narrowing of the airways and recurrent episodes of breathlessness, wheezing, and chest tightness. Recent estimates from the World Health Organization (WHO) suggest that asthma affects the lives of more than 235 million people worldwide [1]. Studies show that

patients with asthma often develop a progressive decline in lung function which is correlated with both the severity and duration of asthma [2].

Research conducted by the Centers for Disease Control and Prevention (CDC) shows that out of the 22 million Americans who have been diagnosed with asthma, 12 million have experienced an asthma episode over the past year [3]. This highlights that many patients have sub-optimally controlled asthma and may benefit from engaging in self-management behaviors. Asthma self-management refers to the daily activities that patients can undertake in order to keep their illness under control, minimize its symptoms and impact on physical health, and help cope with its psychosocial sequelae [4].

Self-management behaviors include self-observation (e.g., monitoring symptoms), self-judgment (e.g., evaluating asthma severity using information collected during the process of self-observation), and self-reaction (e.g., how an individual responds to self-observations and self-judgments) [5]. Clinicians commonly ask patients to self-monitor (or self-observe) their asthma symptoms and lung function in order to make informed decisions about whether treatment regimens are effectively controlling asthma and whether escalation of therapy is warranted [6]. Indeed, symptom self-monitoring can be extremely useful in

This article is part of the Topical Collection on *Allergies and the Environment*

✉ Delesha M. Carpenter
dmcarpenter@unc.edu

¹ Eshelman School of Pharmacy, University of North Carolina, 1 University Heights, CPO 2125, Asheville, NC 28804, USA

² School of Pharmacy, University College London, 29-39 Brunswick Square, Bloomsbury, London WC1N 1AX, UK

³ School of Medicine, University of North Carolina, 104 Mason Farm Road, CB #7310, Chapel Hill, NC 27599-7310, USA

⁴ Department of Practice and Policy, Centre for Behavioural Medicine, UCL School of Pharmacy, Mezzanine Floor, Entrance A, Tavistock House North, Tavistock Square, London WC1H 9HR, UK

preventing future exacerbations, reducing emergency department visits, and keeping asthma well controlled [7].

Self-monitoring of lung function by measuring the peak expiratory flow (PEF) and forced expiratory volume in 1 s (FEV₁) is often recommended for children and adults with persistent asthma [8]. These lung function parameters are indicators of airflow obstruction and provide useful information about the patient's asthma severity [9]. Devices such as peak flow meters (PFMs) and spirometers are considered important tools for the monitoring and assessment of PEF and FEV₁. Thus, the use of such devices can result in information (e.g., lung function results) that influences how patients judge the severity of their asthma and their subsequent reactions (e.g., calls the doctor, takes rescue medications, etc.)

In recent years, the desire to facilitate patients' ability to monitor their lung function from a home setting and without clinical supervision has led to the development of handheld, portable, electronic spirometers which can measure, store, and download the results of multiple lung function tests onto personal electronic devices such as smart phones and computers [7]. The usefulness of portable spirometers for asthma self-management depends on their ability to provide patients with objective and reliable measurements of pulmonary function [7]. Lung function tests are highly effort dependent and pose challenges for many patients. Therefore, differences in spirometer features and quality of instruction on how to perform the breathing maneuvers required for spirometry may impact whether patients use the device correctly. In the past, patients have used PFMs to manually record their peak expiratory flow in paper or electronic diaries. Despite provider requests to have patients document PEF, many patients did not record PEF because they found the process burdensome or unhelpful [10, 11]. The use of electronic home spirometers may be less burdensome to patients and facilitate accurate documentation of lung function by allowing patients to electronically log data and receive feedback on whether they performed a high-quality lung function test [12, 13].

Given the relative newness of most portable electronic spirometers, a review of the capabilities of existing spirometers is currently lacking in the published literature. Thus, our aim was to address this gap in the literature and review portable, electronic spirometers that are currently available and marketed for use with asthma patients. This review focuses on the features of the spirometers that could influence patient uptake (e.g., cost) and use (e.g., how results are displayed) in order to help clinicians make informed decisions about which spirometers may most benefit their patients.

Methods

Search Strategy

A systematic review was conducted in December 2017 to identify portable electronic spirometers available on the

market which are capable of monitoring lung function and providing asthma patients with feedback on their lung function tests. We searched for electronic spirometers using both PubMed and Google.

First, a PubMed search without any publication data restrictions was conducted using the following search terms:

("electronics"[MeSH Terms] OR "electronics"[All Fields] OR "electronic"[All Fields]) AND portable [All Fields] AND spirometer [All Fields] AND ("patients"[MeSH Terms] OR "patients"[All Fields] OR "patient"[All Fields])

Abstracts were reviewed for relevance and excluded from further review if they did not reference (1) electronic spirometers, (2) lung function monitoring, (3) asthma monitoring devices, or (4) names of devices/apps associated with asthma monitoring. Full texts of potentially relevant articles were then obtained and reviewed in detail. Additionally, the references of those articles were examined to determine if there were additional devices that were not captured during the original PubMed search.

Given the low yield of the PubMed search, we then conducted a Google search to identify portable electronic spirometers that may have been developed but not yet reported in the academic literature. The Google search was conducted by two researchers (R.J. and C.R.) who independently reviewed the first 100 search results. The researchers used the following search terms: "spirometer AND Asthma AND portable OR handheld AND electronic." Search results were flagged for further review if they referenced (1) electronic spirometers, (2) lung function monitoring, (3) asthma monitoring devices, and (4) names of devices/apps associated with asthma. The two researchers (R.J. and C.R.) then met and reached consensus on which devices should be included for further review.

Last, because many of the electronic spirometers identified during the Google search had associated mobile applications (apps), two researchers (R.J. and C.R.) also reviewed all search results on Apple's App Store and Google Play using the following search terms "spirometry" and "spirometer" to identify additional devices that may not have populated during the Google or PubMed searches.

Inclusion Criteria

Two coders met to reach consensus on which devices met the inclusion criteria. Devices met inclusion criteria if they (1) were electronic, (2) were handheld/portable or "pocket-sized," (3) could be used with mobile devices/tablets/health apps, (4) were indicated for asthma, (5) were intended for patient use, (6) were interactive (i.e., provided patients with feedback/videos/alerts/instructions), (7) allowed data syncing of results onto personal devices, and (8) measured lung function parameters relevant to asthma such as PEF and FEV₁. Devices were excluded if they were (1) not used for asthma (for example, devices exclusively for chronic obstructive pulmonary disease

(COPD) or cystic fibrosis (CF)) or (2) intended solely for use by healthcare professionals (e.g., physicians, nurses, respiratory therapists).


Data Extraction and Analysis

For those devices that met inclusion criteria, two coders (R.J. and C.R.) independently extracted the following information: (1) name of device, (2) other non-asthma indicated diseases (COPD, CF, other), (3) target users (i.e., patient, provider, other), (4) lung function tests performed, (5) type of feedback provided to users, (6) whether the device’s app included instructional videos on how to perform breathing maneuvers correctly, (7) additional device features, (8) data on the relationship between use of the device and patient outcomes as reported in peer-reviewed publications, (9) operating platform (i.e., iOS, Android), (10) FDA approval status, (11) whether data are stored in a secure manner, and (12) the measurement accuracy of the device. The two coders discussed coding discrepancies and reached consensus on data that were extracted for all devices.

Results

The search strategy yielded 36 devices, 16 of which met inclusion criteria (Fig. 1). Table 1 presents an overview of the data that were coded from the 16 devices.

Fig. 1 Overview of portable electronic spirometer selection process



Indicated Diseases

Although all 16 devices were designed for use with patients with asthma, most were also designed for use in patients with other respiratory diseases. For instance, ten devices (62.5%) also targeted COPD, six devices (37.5%) targeted CF, and five (31.3%) targeted other pulmonary disorders such as bronchitis and emphysema. Three devices (18.8%) were also marketed to patients to monitor lung function after lung transplant surgeries.

Target User

Only three devices (18.8%) were targeted specifically to patients. The remaining 13 devices (81.3%) were targeted to both patients and their healthcare providers. Out of those 13 devices, one device (Wing) also targeted athletes, runners, swimmers, and musicians who were interested in monitoring their lung function.

Lung Function Tests Performed

All 16 devices provided testing for PEF and FEV₁. Thirteen devices (81.3%) also allowed patients to measure forced vital capacity (FVC), which is another measure of airway obstruction. Half of the devices measured FEF₂₅₋₇₅, which is an indicator of how the smaller airways have been affected by asthma. Furthermore, seven devices (43.8%) measured the FEV₁/FVC ratio, three devices (18.8%) measured FEV₆ (forced expiratory volume in 6 s), two devices (12.5%)

Table 1 Key aspects of electronic portable spirometers capable of monitoring lung function from home

Name of device	Indicated diseases	Target user	Commonly used asthma-related lung function tests	Feedback given	Instructional videos	Additional features	Patient outcome data
GoSpiro	Asthma, COPD, CF, IPF, and other pulmonary disease	Patients and health providers	FVC, FEV ₁ , PEF, FEV ₇₅ , FEV ₂₅₋₇₅ , FEV ₆ , SVC, and others	<ul style="list-style-type: none"> Real-time patient coaching on technique Test results dashboard with patient feedback for comparison Immediate feedback provided on quality of patient test performance Graphs as well as yellow, red, and green lights for pulmonary status “poor blast” alert to notify patient of poor performance Results compared to reference values Detects poor blows Coaches patients to perform test correctly Real-time asthma risk prediction Green, yellow, red zone 	No	<ul style="list-style-type: none"> Portal connects patients to physicians Automated medication and appointment reminders Asthma questionnaire 	No
Aeres	Asthma	Patients	FEV ₁ , FVC, PEF	<ul style="list-style-type: none"> Graphs as well as yellow, red, and green lights for pulmonary status “poor blast” alert to notify patient of poor performance Results compared to reference values Detects poor blows Coaches patients to perform test correctly Real-time asthma risk prediction Green, yellow, red zone 	Yes	<ul style="list-style-type: none"> Game available to guide patients through pulmonary test maneuver (hot air balloon) 	No
VitalFlo	Asthma	Patients and health providers	PEF, FEV ₁ , FVC, FEV ₂₅₋₇₅	<ul style="list-style-type: none"> Chart/graph, instant messages such as “your asthma seems under control,” and real-time feedback to ensure appropriate technique 	No	<ul style="list-style-type: none"> Asthma trigger monitoring Connects to doctor Asthma control survey Medication use survey 	No
mSpirometer	Asthma, COPD	Patients and health providers	PEF, FEV ₁ , FVC	<ul style="list-style-type: none"> Chart/graph, instant messages such as “your asthma seems under control,” and real-time feedback to ensure appropriate technique 	No	<ul style="list-style-type: none"> Medication reminders Symptoms and environmental trigger recording Track inhaler use, and sync with healthcare providers and caregivers Instant messaging with provider Tracks medications and medication reminders, triggers, and symptoms (questionnaire) Estimates personal best goals (peak flow and FEV₁ goals based on age, height, gender, and ethnicity) Monthly report sent to physicians, family, and friends Game Scores symptoms and add notes to each section (e.g., “starting to feel well, getting over the cold”) Sharing notes with doctor Game for starting spirometry (incentive) Oximetry Pediatric incentive Warnings for triggers Inhaler management Send data to doctor (possible video consultations) Temperature sensor, pressure sensor, humidity sensor Pulse oximetry sensor 	No
Wing	Asthma, COPD, CF	Patients and health providers, athletes, musicians, singers	FEV ₁ , PEF	<ul style="list-style-type: none"> Green, yellow, and red zone (tracking and graphical trends) Messages such as “Your asthma is doing great! Continue taking your daily meds as prescribed.” 	Yes	<ul style="list-style-type: none"> Instant messaging with provider Tracks medications and medication reminders, triggers, and symptoms (questionnaire) Estimates personal best goals (peak flow and FEV₁ goals based on age, height, gender, and ethnicity) Monthly report sent to physicians, family, and friends Game Scores symptoms and add notes to each section (e.g., “starting to feel well, getting over the cold”) Sharing notes with doctor Game for starting spirometry (incentive) Oximetry Pediatric incentive Warnings for triggers Inhaler management Send data to doctor (possible video consultations) Temperature sensor, pressure sensor, humidity sensor Pulse oximetry sensor 	No
MIR Spirobank Smart [15, 27]	Asthma, COPD, CF, lung transplant	Patients and health providers	PEF, FVC, FEV ₁ , FEV ₁ /FVC, FEV ₆ , FEV ₂₅₋₇₅	<ul style="list-style-type: none"> Indication of “good blow” Test messages such as “test in progress, blow out faster” Motivational graphics Green, yellow, and red alerts (traffic light health indicators) Graphs and charts 	Yes	<ul style="list-style-type: none"> Indication of “good blow” Test messages such as “test in progress, blow out faster” Motivational graphics Green, yellow, and red alerts (traffic light health indicators) Graphs and charts 	No
MySpiroo [28]	Asthma, COPD	Patients and health providers	FVC, FEV ₁ , PEF, FEV ₂₅₋₇₅	<ul style="list-style-type: none"> Graphical display Green for normal FVC status 	Yes	<ul style="list-style-type: none"> Graphical display Green for normal FVC status 	No (unpublished data are publicly available)

Table 1 (continued)

Name of device	Associated app and platform	FDA approval	Data security	Cost	Accuracy of device	
SmartOne	Asthma, COPD, lung transplant, CF	Patients and health providers	FEV ₁ , PEF	Yes	<ul style="list-style-type: none"> - Support in different languages - Includes an incentive program for adults and children - Symptom monitoring - Medication reminder - Allows result sharing with doctors - Buzzer to coach beginning and end of tests - Oximetry - Allows self-tracking of symptoms - Allows physicians to monitor patient performance 	No
Spiroedge	Asthma	Patients	FVC, FEV ₁ , FEV ₁ /FVC, PEF ₂₅₋₇₅ , PEF	No	<ul style="list-style-type: none"> - Green, yellow, and red zone - Traffic light health indicator - Feedback on blow and performance - Results for lung function test provided within 15 s 	No
MobileSpiro	Asthma and other respiratory diseases	Patients and health providers	PEF, FVC, FEV ₁ , FEV ₁ /FVC, FEF ₂₅₋₇₅	No	<ul style="list-style-type: none"> - Gives patient direct feedback on how to blow and exhale to ensure quality test - Real-time graph of flow and volume versus time, which serves to motivate the patient to give his or her best effort - Traffic light system placing patients in different zones - Graphical display of results 	No
Spiromagic	Asthma, COPD, or others interested in home fitness monitoring	Patients and health providers	FEV ₁ , FEV ₆ , PEF, FEV ₁ /FEV ₆	No	<ul style="list-style-type: none"> - Blowing game to guide users 	No
AirSmart	Asthma, COPD, CF, bronchitis, emphysema, lung transplant, and many more respiratory diseases	Patients and health providers	FEV ₁ , FVC, FEV ₁ /FVC, PEF	No	<ul style="list-style-type: none"> - Graphical display and coaching to ensure quality test, e.g., "it seems like you started your exhale a bit too slow. Exhale faster, do not hesitate," A, B, C, D, and F (very good, good, poor, not acceptable) 	No
SpiroSmart [29]	Asthma and other pulmonary and respiratory diseases	Patients	PEF, FEV ₁ , FVC, FEV ₁ /FVC	No	<ul style="list-style-type: none"> - Blowing game to guide users 	No
Spirotube	Asthma, COPD	Patients and health providers	PEF, FEV ₁ , FEF ₂₅₋₇₅ , and others	No	<ul style="list-style-type: none"> - Number, graph and voice feature such as "you have mild restriction" with mild restriction written on screen 	No
SpiroHome	Asthma, COPD, CF	Patients and health providers	PEF, FEV ₁ , FVC, FEF ₂₅₋₇₅	No	<ul style="list-style-type: none"> - Graphical display, animation (frowny face with "you did not perform test correctly") 	No
Pulmo	Asthma	Patients and health providers	FEV ₁ , FVC, PEF	No	<ul style="list-style-type: none"> - Graphical display of results 	No
Name of device	Associated app and platform	FDA approval	Data security	Cost	Accuracy of device	
GoSpiro	GoSpiro (Android and iOS)	Yes	<ul style="list-style-type: none"> - No personal info stored on device; password protection - Secure bidirectional transfer of data between patients and physicians 	Spirometer: not available App: free	<ul style="list-style-type: none"> - Volume accuracy: ±3% of reading, or 0.05 L - Flow sensitivity: better than 0.025 L/s 	
Aeres	Aeres (iOS)—currently unavailable	Pending	Data not available	Spirometer: \$180 App: \$10 monthly fee	<ul style="list-style-type: none"> - FEV₁ accuracy: ±3% - PEF accuracy: ±3% 	
VitalFlo mSpirometer	App for iOS Asthmahero mobile app BreatheSmart® mobile app [14] (Android and iOS)	Seeking Yes	HIPAA-compliant servers HIPAA-compliant cloud server upload	To be determined Spirometer: not available App: free	<ul style="list-style-type: none"> - "Clinical grade accuracy" - "Clinical grade accuracy" 	
Wing	Wing (iOS)	Yes		Spirometer: \$99		

Table 1 (continued)

				Synced to cloud with 256-bit encryption			App: free	Meets ATS standard for measuring FEV ₁ and peak flow Automatic reproducibility checks FEV ₁ : ±0.1 L or ±5% Peak flow: ±20 L/min or ±10% Flow range: ±16 L/s Volume accuracy: ±3% or 50 mL Flow accuracy: ±5% or 200 mL/s “Equivalent to hospital spirometers”
MIR Spirobank Smart [15, 27]	iSpirometry (Android and iOS) MIR Spiro (iOS)	Yes	Data not available	Data not available			Spirometer: \$1390 App: free	
MySpiroo [28]	MySpiroo Clinic (iOS and Android)	No	Data not available	Data not available			Spirometer: not available	
SmartOne	MIR SmartOne (iOS and Android)	Pending	Data not available	Data not available			App: free Spirometer: \$155	Data not available
Spiroedge	App for Android	No	Personal Bluetooth code to ensure safe connection, HIPAA compliant	Data not available			App: free	Data not available
MobileSpiro	App for Android	No	Data not available	Data not available			Not available	94%; with an inter-device deviation in flow reading of less than 8%, and detects more than 95% of erroneous cough maneuvers in a public CDC dataset Data not available
Spiromagic	Spiromagic for iOS	No	Results are stored in a “secure database”	Data not available			Spirometer: \$187	
AirSmart	Air Smart Spirometer (iOS and Android)	No	HIPAA and GDPR compliant	Data not available			App: free Spirometer: \$231	Clinical grade accuracy Volume accuracy ±3% or 50 mL Flow accuracy ±5% or 200 mL Spirosmart app at 5.1% accuracy of commercial spirometers
SpiroSmart [29]	App for iOS	Seeking	Data not available	Data not available			“Low cost to be determined”	FVC is within the range of expected variability almost 80% of the time and PEF over 90% of the time Flow precision: 2% Flow range: ±18 L/s
Spirotube	SpiroID (Android) ThorSoftME (Android)	No	Data not available	Data not available			Spirometer: not available	
SpiroHome	Spirohome (Android)	Seeking	Secure cloud-based storage	Data not available			App: free Spirometer: not available	“High accuracy”; “as accurate as a spirometer you would see in a hospital”
Pulmo	Pulmo App for Android	No	Data not available	Data not available			App: free Spirometer: \$128	Data not available

COPD chronic obstructive pulmonary disease, *CF* cystic fibrosis, *IPF* idiopathic pulmonary fibrosis, *FEF₂₅₋₇₅* mean forced expiratory flow during the middle half of the FVC curve, *FEV₁* forced expiratory volume in 1 s, *FEV₁/FVC* ratio of FEV₁ to FVC, *FEV₆* forced expiratory time in 6 s, *FVC* forced vital capacity, *PEF* peak expiratory flow, *SVC* slow vital capacity

measured the FEV₁/FEV₆ ratio, and one device (6.3%) measured slow vital capacity (SVC).

Feedback Given

Ten devices (62.5%) provided graphical representations of lung function results. Seven (43.8%) gave patients immediate visual or audio feedback on whether they had performed the test correctly. Six devices (37.5%) had a traffic light system indicating whether patients' pulmonary status was in the red (danger zone), yellow (caution), or green (safe) zone.

Instructional Videos

Only five devices (31.3%) had instructional videos available within the app to provide patients with guidance on how to use the device and how to perform the breathing maneuvers correctly. The remaining 68.8% did not have instructional videos available directly on the device or app. Instead, some had graphical or text instructions or posted videos on the manufacturer's website or YouTube.

Additional Features

Nearly all devices (75%), either directly or via their associated apps, allowed patients to share lung function test results with their healthcare provider. Four devices (25%) included incentive features such as games to motivate patients to perform their lung function test correctly. Six devices (37.5%) had other self-management features, such as a medication tracking feature as well as symptom monitoring and asthma trigger alert features. Three devices (18.8%) had an additional oximetry option which allowed for the monitoring of oxygen saturation.

Patient Outcome Data

Data on the relationship between use of these devices and patient outcomes have not yet been published in peer-reviewed journals. However, a 6-month trial on the use of the mSpirometer in conjunction with an inhaler monitoring device and medication reminder system has been reported and found a positive association with medication adherence [14].

App Platform

The MIR Spirobank Smart and Spirotube both had two apps that could be used with the device. Six of the spirometer apps (33.3%) were designed exclusively for iOS platforms and six of the apps (33.3%) were exclusively for Android platforms. The other six apps (33.3%) were available on both iOS/Android platforms.

FDA Approval

Four devices (25%) had been approved by the FDA. Seven devices (43.8%) were not FDA approved, two (12.5%) were pending FDA approval, and three devices (18.8%) were currently seeking FDA approval.

Data Security

Ten devices (62.5%) did not provide any information regarding how data security was addressed. Four devices (25%) used Health Insurance Portability and Accountability Act (HIPAA) compliant servers and two (13.8%) provided password-based protection of data. Others claimed to have "secure databases" or "secure bi-directional transfer of data" but did not specify how data were protected.

Cost

Information on cost was only available for seven devices. The prices ranged from US\$99 to \$1390. The majority (six out of seven) cost less than \$200. The apps associated with the devices were available for free, with the exception of one app (Aeres) which required a \$10/month fee.

Measurement Accuracy

The accuracy of eight devices (50%) was not publicly available. However, four of the eight devices claimed that the device met hospital and clinical grade accuracy. Two devices (12.5%), AirSmart and MIR Spirobank Smart, claimed the following: volume accuracy $\pm 3\%$ or 50 mL and flow accuracy $\pm 5\%$ or 200 mL. Another device, Wing, claimed to meet American Thoracic Society (ATS) standards for measuring FEV₁ and peak flow (FEV₁, ± 0.1 L or $\pm 5\%$; peak flow, ± 20 L/min or $\pm 10\%$). The remaining devices had varying accuracy values (Table 1). Studies have been published that compare the accuracy of several devices (MIR Spirobank [15], MobileSpiro [16], AimSmart [17], Wing [18]) with standard spirometers.

Discussion

This review is the first to summarize the key features of portable electronic spirometers that have been developed to help patients with asthma monitor their lung function at home. Portable technology that uses sensors and smartphones to measure lung function is becoming increasingly prevalent [19], and home spirometry is acquiring more acceptance because of its potential to help patients detect exacerbations, manage their condition, and improve the overall outcomes of chronic lung conditions. This review highlights both the

promise and current shortcomings of portable electronic spirometers to enhance at-home monitoring of lung function.

A variety of portable electronic spirometers are commercially available, and lung function test capabilities of these spirometers commonly include PEF and FEV₁. However, lung function test results have little meaning to patients and providers unless they are compared against specific reference values [20] since these reference values allow one to determine the extent of airway obstruction [21]. To be most useful, lung function tests should present results in relation to what would be predicted given the user's age, ethnicity, gender, and smoking status. Hence, portable spirometers should allow users to enter their demographic data in order to get customized lung function results, rather than using a "one size fits all" referencing approach. However, this recommendation comes with the caveat that all data should be stored securely so that the user's personal health information is not at risk of being stolen. Many devices did not address how data were secured, which is a major shortcoming that needs to be addressed by device manufacturers.

Although many devices provided patients with graphical representations of their lung function results, in many cases, these data were not in a form that would be easy to understand for a layperson. An exception are those devices that incorporated a "traffic light system" feature which could facilitate patients' ability to self-judge whether their asthma is within the green (safe) zone, yellow (caution), or red (danger) zone based on their lung function test results. This can not only motivate patients who have their asthma under control to continue engaging in self-monitoring behavior but it also can alert patients who fall under the yellow or red zones that they are at greater risk of an asthma exacerbation.

Almost half of the devices included in this review provided patients with feedback on the quality of their test performance, allowing users to know when they have performed a "poor blow" or if they needed to repeat the test. Without adequate feedback, patients may not be aware of when they performed a lung function test incorrectly, which may in turn lead to inaccurate results, inappropriate action, or further confusion. Thus, it is important for devices to provide patients with feedback on the quality of their test performance. In addition to ensuring that the quality of results is not jeopardized, the integration of feedback and coaching features could potentially improve patient adherence if they see that their lung function improves when they adhere to their treatment regimen. For example, some of the devices included messages such as: "Your asthma is doing great! Continue taking your daily medicines as prescribed." However, apps that include treatment recommendations need FDA approval, which may limit the number of devices that provide guidance on what actions to take when a test reveals poor lung function results.

Studies have highlighted differences in the quality and accuracy of lung function measurements collected with portable

electronic spirometers, with some devices providing more reliable and accurate data than others [15–18, 22]. Accuracy of lung function data is especially important given that valid spirometry testing requires substantial effort while exhaling to yield accurate results. Even though some of these devices offer games and incentives to encourage accurate test performance, most fail to take into account some factors that may affect patients' ability to perform a test correctly, such as age or asthma severity. For example, children may have more difficulty performing a PEF or FEV₁; thus, they may need additional guidance to ensure a high quality test. Therefore, additional modifications to the devices may be required to create suitable coaching methods for specific patient groups who might find spirometry more challenging [19].

The convenience and accessibility of a personal portable spirometer may encourage patients to self-monitor (or self-observe) their lung function more often. Most of the asthma apps associated with the spirometers were free to download. Moreover, mobile phones are generally affordable, widely used, and discrete, which makes regular monitoring of lung function more accessible and convenient for patients than ever before. This is especially true given that traditional spirometers are generally larger, more expensive, require calibration, and cannot be easily used outside a clinical setting [23]. Also, the apps associated with these spirometers allow patients to collect lung function data themselves, which in turn seems to be slowly disrupting the traditional practice of office or clinic-based monitoring of lung function [23]. Indeed, the majority of these devices enable patients to transfer their lung function test results directly to their healthcare providers, which could facilitate patient–provider communication about asthma by allowing providers to track their patients' overall pulmonary status without the necessity of an appointment. For example, data collected from the symptom diary features of the mobile phone apps can be used to determine the effectiveness of treatment [24]. As with most long-term diseases, healthcare professionals have begun to explore the concept of mobile technology as a means of communicating with patients and collecting health information more efficiently [25].

Although these devices are convenient to use, patients may not use them on a regular basis over longer periods of time. In the past, patient adherence to peak flow monitoring was often low due to perceived burden of testing or low perceived usefulness [10, 11]. Currently, only 25% of devices included motivational features to encourage patients to perform the test correctly. Additional motivational features, such as games or incentives, may be needed to promote long-term self-monitoring with portable electronic spirometers.

Regular spirometry testing can result in earlier detection of exacerbations, quicker recovery times, earlier treatment, reduced health costs, and an overall improved quality of life [26], yet patients' ability to engage in spirometry at home could be limited by several factors, including the platform of

the device's app (iOS/Android), lack of FDA approval, and cost. If the patients' smartphone or tablet platform does not match the device's app, then they cannot use that device. Also, providers may feel uncomfortable recommending a device that is not FDA approved to patients.

We identified several key areas for potential future research that may lead to the development of improved electronic spirometers for the monitoring of asthma from a home setting. First, studies on the relationship between use of these devices and patient outcomes are greatly needed so that providers and patients can make an informed decision about whether these devices could be potentially beneficial for improving asthma outcomes. Data on whether using these devices results in better asthma control and less health service utilization (e.g., asthma-related emergency department visits, hospitalizations, and unscheduled office visits) as well as data on adoption and continued use of the device over time are particularly needed. Longitudinal studies that compare the effectiveness of portable electronic spirometers with usual care will help providers truly understand the impact that these devices can have on self-management and clinical outcomes. Second, only a few devices' apps included instructional videos on breathing maneuvers, which is a serious shortcoming given that significant patient effort is needed to yield a high-quality test. Therefore, we recommend that all portable, electronic spirometers include instructions that are easy to access in the spirometer's app. Additionally, apps should present spirometry results in a way that is easy for patients to understand. Devices that provide feedback that is difficult to interpret could lower users' perceived usefulness of the device, especially for patients with low health literacy [23]. Moreover, patients' involvement and engagement in self-monitoring could be negatively impacted if they do not understand the results. Third, more studies should be conducted on the usability and accuracy of these devices. Often, there was not enough published data to confirm the manufacturer's claims regarding the accuracy of their devices.

Limitations

It is likely that our search strategy did not capture all portable electronic spirometers intended for home use with asthma patients. We limited our search to PubMed and Google, as we felt non-academic search engines may yield more results because many commercial devices are not used in published studies. However, other databases such as Cochrane and EMBASE may have yielded additional devices. Also, we were unable to obtain some information (e.g., cost) on spirometers. Despite our efforts to contact different manufacturers to supplement missing information, insufficient publicly available detail may have resulted in misinterpretations of data during the extraction process. In order to minimize coding

inaccuracies, two independent researchers coded all device features and met to resolve discrepancies in coding. In addition, our review did not include spirometers that did not have an associated app. We chose to focus on spirometers that had apps since these spirometers would be more likely to present lung function data to patients. Spirometers without apps may include different features that could be of great use to the patient; thus, our results should not be extrapolated to portable spirometers that do not have apps. Also, we mainly focused on whether certain device features were present rather than the actual quality of the feature. Future work could examine user ratings on the App store and Google Play store as well as collect usability data from patients to understand the quality of various spirometer and app features.

Conclusions

As the number of portable, electronic spirometers continues to increase, it is important that clinicians and patients are able to easily evaluate each spirometer's strengths and weaknesses in order to make an informed decision about which spirometer best meets the patient's needs. Although all spirometers were capable of providing patients with useful information about their lung function, many devices had several limitations related to a lack of instructions on how to perform breathing maneuvers correctly and did not provide feedback on lung function results in a way that is easy for patients to understand. Additionally, many devices may be inaccessible to patients due to high cost, app platform (iOS vs. Android), and lack of FDA approval. Due to the lack of data on whether use of these spirometers is associated with improved patient outcomes, including clinical outcomes, providers may want to work with patients on an individual basis to determine whether they believe using these devices may benefit patients via increased self-monitoring of lung function at home.

Acknowledgements None.

Funding The authors did not receive any funding for this study.

Compliance with Ethical Standards

Conflict of Interest D.M.C. and C.A.R. currently have a contract from VitalFlo, Inc. to conduct a usability study of the VitalFlo spirometer. R.H. reports grants from National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) North Thames, during the conduct of the study; grants from Asthma UK Centre for Applied Research (AUKCAR), other from Medical Innovation Academic Consortium (CASMI), other from AbbVie, other from Amgen, other from Biogen, other from Idec, other from Gilead Sciences, other from GlaxoSmithKline, other from Janssen, other from Pfizer, other from Roche, other from Shire Pharmaceuticals, other from MSD, other from Astellas, other from AstraZeneca, other from DRSU, other from Novartis, other from Universitätsklinikum Hamburg-Eppendorf, other from Teva

Pharmaceuticals, and other from Spoonful of Sugar Ltd., outside the submitted work. A.C. reports grants and personal fees from Janssen-Cilag, other from Medicines NZ, personal fees from Novartis, grants from Asthma UK Centre for Applied Research (AUKCAR), personal fees from Spoonful of Sugar Ltd., grants from Innovate UK, grants from A+ charitable trust (Auckland District Health Board), and grants from Maurice and Phyllis Paykel Trust, outside the submitted work. R.J. declares no conflicts of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major Importance

1. World Health Organization. Chronic Respiratory Diseases: Asthma. <http://www.who.int/respiratory/asthma/en/>. Accessed 3 Aug 2018.
2. Kupczyk M, Kuprys I, Gorski P, et al. Long-term deterioration of lung function in asthmatic outpatients. *Respiration*. 2004;71(3):233–40.
3. Centers for Disease Control and Prevention National Asthma Control Program. America Breathing Easier. https://www.cdc.gov/asthma/pdfs/breathing_easier_brochure.pdf. Accessed 3 Aug 2018.
4. Mammen J, Rhee H. Adolescent asthma self-management: a concept analysis and operational definition. *Pediatr Allergy Immunol Pulmonol*. 2012;25(4):180–9.
5. Carpenter DM, Gerk LL, Sage A, et al. Exploring the theoretical pathways through which asthma app features can promote adolescent self-management. *Transl Behav Med*. 2016;6(4):509–18.
6. Stoloff SW, Janson S. Providing asthma education in primary care practice. *Am Fam Physician*. 1997;56(1):117–26. 31-4, 42
7. Tovar JM, Gums JG. Monitoring pulmonary function in asthma and COPD: point-of-care testing. *Ann Pharmacother*. 2004;38(1):126–33.
8. Woodruff PG, van den Berge M, Boucher RC, Brightling C, Burchard EG, Christenson SA, et al. American Thoracic Society/ National Heart, Lung, and Blood Institute asthma-chronic obstructive pulmonary disease overlap workshop report. *Am J Respir Crit Care Med*. 2017;196(3):375–81.
9. Turner-Warwick M. On observing patterns of airflow obstruction in chronic asthma. *Br J Dis Chest*. 1977;71(2):73–86.
10. Harver A, Humphries CT, Kotses H. Do asthma patients prefer to monitor symptoms or peak flow? *J Asthma*. 2009;46(9):940–3.
11. McMullen AH, Yoos HL, Kitzman H. Peak flow meters in childhood asthma: parent report of use and perceived usefulness. *J Pediatr Health Care*. 2002;16(2):67–72.
12. Sly PD, Flack F. Is home monitoring of lung function worthwhile for children with asthma? *West J Med*. 2001;175(5):344–5.
13. Hyland M, Kenyon CA, Allen R, et al. Diary keeping in asthma: comparison of written and electronic methods. *BMJ*. 1993;306(6876):487–9.
14. Melvin E, Cushing A, Tam A, Kitada R, Manice M. Assessing the use of BreatheSmart® mobile technology in adult patients with asthma: a remote observational study. *BMJ Open Respir Res*. 2017;4:e000204. <https://doi.org/10.1136/bmjresp-2017-000204>.
15. Degryse J, Buffels J, Van Dijck, et al. accuracy of office spirometry performed by trained primary-care physicians using the MIR Spirobank hand-held spirometer. *Respiration*. 2012;83(6):543–52.
16. Gupta S, Chang P, Anyigbo N, et al. mobileSpiro: accurate mobile spirometry for self-management of asthma. In: Proceedings of the First ACM Workshop on Mobile Systems, Applications, and Services for Healthcare. 2011. <https://doi.org/10.1145/2064942.2064944>.
17. Hernández CR, Núñez Fernández M, Pallares Sanmartín A, et al. Validation of the portable Air-Smart Spirometer. *PLoS One*. 2018;13(2):e0192789.
18. Sumino K, Cohen A, Patterson BM, et al. Accuracy of smartphone-based spirometry (WING) use at home in asthma. In A34. ASTHMA CLINICAL STUDIES I. Thematic poster session. American Thoracic Society; 2018. pp. A1377–A1377.
19. Kwan AM, Fung AG, Jansen PA, Schivo M, Kenyon NJ, Delplanque JP, et al. Personal lung function monitoring devices for asthma patients. *IEEE Sensors J*. 2015;15(4):2238–47.
20. Larson EC, Saba E, Kaiser S, Goel M, Patel SN. Pulmonary monitoring using smartphones, in mobile health: sensors, analytic methods, and applications. In: Rehg J, Murphy S, Kumar S, editors. *Mobile health*. Cham: Springer International Publishing; 2017. p. 239–64.
21. Yun TJ, Arriaga RI. A text message a day keeps the pulmonologist away. In Proceedings of the SIGCHI Conference on Human Factors in Computing Systems. 2013. <https://www.cc.gatech.edu/fac/arriaga/YunArriagaCHI13.pdf>. Accessed 3 Aug 2018.
22. Godschalk I, Brackel HJ, Peters JC, et al. Assessment of accuracy and applicability of a portable electronic diary card spirometer for asthma treatment. *Respir Med*. 1996;90(10):619–22.
23. Sowman G, Wheatley A, Miller J, et al. Quality of home spirometry data in asthmatic patients. *Eur Respir Soc*. 2013;42(57):1257.
24. Rehg, JM, Murphy SA, and Kumar S. *Mobile health: sensors, analytic methods, and applications*. Springer International Publishing; 2017.
25. International Organization for Standardization, ISO 9241-210: 2010. Ergonomics of human system interaction—Part 210: Human-centred design for interactive systems. Switzerland, 2009.
26. Birch D. Breathe easy: developing a low-cost, highly effective, portable spirometer. 2015. https://www.surrey.ac.uk/mes/research/aef/sensors/Breathe_Easy.pdf. Accessed 3 Aug 2018.
27. Hanif J, Eccles R, Jawad SS. Use of a portable spirometer for studies on the nasal cycle. *Am J Rhinol*. 2001;15(5):303–6.
28. Koltowski L. HealthUp/MySpiroo, patient focused, digital respiratory disease management system. 2018. https://attendris.com/wp-content/uploads/2018/05/RIS2018_DigitalTech_HealthUp.pdf?utm_source=RIS_Agenda&utm_medium=Presentation&utm_campaign=RIS_2018&utm_content=RespiratoryInnovation. Accessed 3 Aug 2018.
29. Larson EC, Goel M, Gaetano B, et al. SpiroSmart: using a micro-phone to measure lung function on a mobile phone. In: Proceedings of the 2012 ACM conference on ubiquitous computing. Association for Computing Machinery. 2012. <https://ubicomplab.cs.washington.edu/pdfs/spirosmart.pdf>. Accessed 3 Aug 2018.